ARTICLE | Company News
Prolysis, The Wellcome Trust infectious news
January 22, 2007 8:00 AM UTC
Prolysis received a £3.5 million ($6.9) award from the Wellcome Trust's Seeding Drug Discovery initiative to develop antibacterials against methicillin-resistant S. aureus (MRSA). The company's CDI-93...